2013 - CTS 2013 Congress


This page contains exclusive content for the member of the following sections: TTS, CTS. Log in to view.

Oral Communications 7

15.2 - Mesenchymal Stromal Cells (MSCs) primed with Paclitaxel as tool for carrying and delivering the drug in cancer therapy

Presenter: Valentina, Cocce, Milan, Italy
Authors: Valentina Coccè1,2,3,4,5, Arianna Bonomi1,2,3,4,5, Loredana Cavicchini1,2,3,4,5, Francesca Sisto1,2,3,4,5, Maura Ferrari1,2,3,4,5, Luisa Pascucci1,2,3,4,5, Giulio Alessandri1,2,3,4,5, Eugenio Parati1,2,3,4,5, Enrico Lucarelli1,2,3,4,5, Augusto Pessina1,2,3,4,5

Mesenchymal Stromal Cells (MSCs) primed with Paclitaxel as tool for carrying and delivering the drug in cancer therapy

Valentina Coccè1,2,3,4,5, Arianna Bonomi1,2,3,4,5, Loredana Cavicchini1,2,3,4,5, Francesca Sisto1,2,3,4,5, Maura Ferrari1,2,3,4,5, Luisa Pascucci1,2,3,4,5, Giulio Alessandri1,2,3,4,5, Eugenio Parati1,2,3,4,5, Enrico Lucarelli1,2,3,4,5, Augusto Pessina1,2,3,4,5

1Department of Biomedical, Surgical, and Dental Sciences, University of Milan, Milan, Italy; 2Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna, Brescia, Italy; 3Department of Biopathological Sciences and Hygiene of Animal and Food Productions, University of Perugia, Perugia, Italy; 4Department of Cerebrovascular Disease, Fondazione IRCCS Neurological Institute C. Besta , Milan, Italy; 5Istituti Ortopedici Rizzoli, IOR, Bologna, Italy

Mesenchymal stromal cells (MSCs) can be easily isolated from bone marrow and adipose tissue and cultured and expanded in vitro. Their  migratory capacity and tropism to solid tumors (both primary and metastatic) have increased the interest in their use as a "carrier" to transport molecules for cancer therapy. Many methodologies  have been described  to create "engineered" MSCs capable of secreting  therapeutic cytokines, pro-drugs or inhibitory factors.
As  previously demonstrated, MSCs derived from human bone marrow, if exposed to high doses of Doxorobicin, are able to inhibit, without any manipulation, the proliferation of hematopoietic stem cells (HSCs). We therefore assessed whether human mesenchymal stromal cells (hMSCs) in vitro loaded with Paclitaxel (PTX), were able to release the drug in sufficient quantity to inhibit the proliferation of tumor cells. The incorporation of the drug into hMSCs was analyzed by FACS and confocal microscopy, using PTX FITC-labeled probe, and the release of PTX in the cellular culture medium (CM) has been demonstrated by liquid chromatography HPLC. The hMSCs loaded with PTX (hMSCsPTX)  show some degree of chemo-apoptosis,  but  80% of the  hMSCsPTX are inhibited to proliferate maintaining their viability and capacity to release  PTX in the CM in a time-dependent manner. The ultrastructural analysis of hMSCsPTX with transmission electron microscope (TEM) showed that the treatment with PTX does not induce morphological alterations. Leukemic cells are attracted and bound by MSCs as demonstrated by the formation of "rosettes" (aggregates of hMSCs surrounded by a "crown" of leukemia cells MOLT-4) in  in vitro co-cultures. The morphology of rosettes analyzed with TEM and SEM (scanning electron microscopy) revealed the presence of cytoplasmic  and nuclear damage in MOLT-4 adherent to hMSCsPTX.
The anti-tumor effects of hMCSsPTX were demonstrated by in vitro experiments: CM obtained from hMSCsPTX inhibit the proliferation of MOLT-4 and other human tumor lines (DU-145 prostate cancer, glioblastoma T98G). Furthermore, in vivo experiments in nude mice have demonstrated that  hMSCsPTX co-injected subcutaneously with tumor cells (MOLT-4, DU145 and U87MG glioblastoma), inhibit the early stages of tumor proliferation; if hMSCsPTX were injected into  preformed tumoral nodules, they reduced the capacity of engraftment and tumor vasculature. We demonstrated that also mature stromal cells, as  human skin derived fibroblasts (hSDFs), had the same properties of hMSCs. In vitro experiments showed that  hSDFs loaded  with PTX (hSDFsPTX) released the drug in a time-dependent manner and  their CM inhibited tumor growth in vitro.
Our data demonstrate that hMSCs, without the need of any genetic manipulation, can be used as "drug carrier" opening their application for new complementary anticancer therapeutic approach.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada